AAAAAA

   
Results: 1-25 | 26-50 | 51-58
Results: 1-25/58
PHARMACOKINETICS AND PHARMACODYNAMICS OF ARGATROBAN AS STUDIED BY HPLC AND FUNCTIONAL METHODS - IMPLICATIONS IN THE MONITORING AND DOSAGE-OPTIMIZATIONS IN CARDIOVASCULAR PATIENTS
Authors: AHMAD S AHSAN A IQBAL O HOPPENSTEADT DA LEWIS BE WALENGA JM FAREED J
Citation: S. Ahmad et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF ARGATROBAN AS STUDIED BY HPLC AND FUNCTIONAL METHODS - IMPLICATIONS IN THE MONITORING AND DOSAGE-OPTIMIZATIONS IN CARDIOVASCULAR PATIENTS, Clinical and applied thrombosis/hemostasis, 4(4), 1998, pp. 243-249
HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS SYNDROME
Authors: WALLIS DE LEWIS BE MESSMORE H WEHRMACHER WH
Citation: De. Wallis et al., HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS SYNDROME, Clinical and applied thrombosis/hemostasis, 4(3), 1998, pp. 160-163
PHARMACOKINETICS AND PHARMACODYNAMICS OF A SYNTHETIC ANTITHROMBIN AGENT, ARGATROBAN, IN MAN AS STUDIED BY HPLC AND FUNCTIONAL METHODS - IMPLICATIONS IN THE MONITORING AND DOSAGE-OPTIMIZATIONS IN CARDIOVASCULARPATIENTS
Authors: AHMAD S AHSAN A IQBAL O HOPPENSTEADT DA LEWIS BE WALENGA JM FAREED J
Citation: S. Ahmad et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF A SYNTHETIC ANTITHROMBIN AGENT, ARGATROBAN, IN MAN AS STUDIED BY HPLC AND FUNCTIONAL METHODS - IMPLICATIONS IN THE MONITORING AND DOSAGE-OPTIMIZATIONS IN CARDIOVASCULARPATIENTS, The FASEB journal, 12(4), 1998, pp. 2368-2368
PATIENT NONCOMPLIANCE IN THE MANAGED CARE SETTING - THE CASE OF MEDICAL THERAPY FOR GLAUCOMA
Authors: GURWITZ JH YEOMANS SM GLYNN RJ LEWIS BE LEVIN R AVORN J
Citation: Jh. Gurwitz et al., PATIENT NONCOMPLIANCE IN THE MANAGED CARE SETTING - THE CASE OF MEDICAL THERAPY FOR GLAUCOMA, Medical care, 36(3), 1998, pp. 357-369
SPECIFIC QUANTITATION OF THROMBIN INHIBITORS USING ECARIN CLOTTING TIME - APPLICATION IN POINT OF CARE TESTING
Authors: IQBAL O AHMAD S HOPPENSTEADT DA LEWIS BE FAREED J
Citation: O. Iqbal et al., SPECIFIC QUANTITATION OF THROMBIN INHIBITORS USING ECARIN CLOTTING TIME - APPLICATION IN POINT OF CARE TESTING, Clinical chemistry, 44, 1998, pp. 221-221
PHARMACOKINETICS AND PHARMACODYNAMICS OF A SYNTHETIC ANTITHROMBIN AGENT, ARGATROBAN, IN MAN AS STUDIED BY HPLC AND FUNCTIONAL METHODS - IMPLICATIONS IN THE MONITORING AND DOSAGE-OPTIMIZATIONS IN CARDIOVASCULARPATIENTS
Authors: AHMAD S AHSAN A IQBAL O HOPPENSTEADT DA LEWIS BE WALENGA JM FAREED J
Citation: S. Ahmad et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF A SYNTHETIC ANTITHROMBIN AGENT, ARGATROBAN, IN MAN AS STUDIED BY HPLC AND FUNCTIONAL METHODS - IMPLICATIONS IN THE MONITORING AND DOSAGE-OPTIMIZATIONS IN CARDIOVASCULARPATIENTS, Clinical chemistry, 44, 1998, pp. 229-229
ACUTE ETA-RECEPTOR BLOCKADE REDUCES PULMONARY VASCULAR-RESISTANCE IN PATIENTS WITH CHRONIC HEART-FAILURE
Authors: GIVERTZ MM COLUCCI WS GOTTLIEB SS HARE JM LEJEMTEL T SLAWSKY MT LEIER C LOH E NICKLAS JM LEWIS BE
Citation: Mm. Givertz et al., ACUTE ETA-RECEPTOR BLOCKADE REDUCES PULMONARY VASCULAR-RESISTANCE IN PATIENTS WITH CHRONIC HEART-FAILURE, Circulation, 98(17), 1998, pp. 3044-3044
PERSISTENCE OF THROMBOTIC COMPLICATIONS IN HEPARIN-INDUCED THROMBOCYTOPENIA PATIENTS AFTER HEPARIN WITHDRAWAL - PROPOSED MECHANISMS OF CONTINUED PLATELET ACTIVATION
Authors: WALENGA JM AHMAD S JESKE WP WOOD J AMIRAL J LEWIS BE
Citation: Jm. Walenga et al., PERSISTENCE OF THROMBOTIC COMPLICATIONS IN HEPARIN-INDUCED THROMBOCYTOPENIA PATIENTS AFTER HEPARIN WITHDRAWAL - PROPOSED MECHANISMS OF CONTINUED PLATELET ACTIVATION, Circulation, 98(17), 1998, pp. 4199-4199
THE FIRST REPORT OF SUCCESSFUL CAROTID STENT IMPLANT USING ARGATROBANANTICOAGULATION IN A PATIENT WITH HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS SYNDROME - A CASE-REPORT
Authors: LEWIS BE RANGEL Y FAREED J
Citation: Be. Lewis et al., THE FIRST REPORT OF SUCCESSFUL CAROTID STENT IMPLANT USING ARGATROBANANTICOAGULATION IN A PATIENT WITH HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS SYNDROME - A CASE-REPORT, Angiology, 49(1), 1998, pp. 61-67
ENHANCEMENT OF COMPLIANCE AMONG PATIENTS WITH HYPERTENSION
Authors: PATTON K MEYERS J LEWIS BE
Citation: K. Patton et al., ENHANCEMENT OF COMPLIANCE AMONG PATIENTS WITH HYPERTENSION, American journal of managed care, 3(11), 1997, pp. 1693-1698
NOVASTAN(R) ANTICOAGULATION DURING RENAL STENT IMPLANT IN A PATIENT WITH HEPARIN-INDUCED THROMBOCYTOPENIA
Authors: LEWIS BE GRASSMAN ED WRONA L RANGEL Y
Citation: Be. Lewis et al., NOVASTAN(R) ANTICOAGULATION DURING RENAL STENT IMPLANT IN A PATIENT WITH HEPARIN-INDUCED THROMBOCYTOPENIA, Blood coagulation & fibrinolysis, 8(1), 1997, pp. 54-58
DIFFERENTIAL-EFFECTS OF ARGATROBAN AND HEPARIN ON HEMOCHRON AND HEMOTEC ACTIVATED CLOTTING TIMES IN PATIENTS UNDERGOING CORONARY INTERVENTIONAL PROCEDURES
Authors: HURSTING MJ BECKER JC LEWIS BE IQBAL O WALENGA JM FERGUSON JJ
Citation: Mj. Hursting et al., DIFFERENTIAL-EFFECTS OF ARGATROBAN AND HEPARIN ON HEMOCHRON AND HEMOTEC ACTIVATED CLOTTING TIMES IN PATIENTS UNDERGOING CORONARY INTERVENTIONAL PROCEDURES, Journal of the American College of Cardiology, 29(2), 1997, pp. 8211-8211
DEVELOPMENT OF A FLOW CYTOMETRIC ASSAY FOR THE LABORATORY DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA
Authors: JESKE W LEWIS BE SZATKOWSKI E FASANELLA A HAAS S WALENGA JM PIFARRE R
Citation: W. Jeske et al., DEVELOPMENT OF A FLOW CYTOMETRIC ASSAY FOR THE LABORATORY DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA, Thrombosis and haemostasis, 1997, pp. 1159-1159
MONITORING OF ANTITHROMBIN DRUGS USING ECARIN CLOTTING TIME - COMPARISON OF DRY-CHEMISTRY AND LIQUID REAGENT
Authors: CALLS D IQBAL O RANGEL Y LEWIS BE MIZE PD HOPPENSTEADT D
Citation: D. Calls et al., MONITORING OF ANTITHROMBIN DRUGS USING ECARIN CLOTTING TIME - COMPARISON OF DRY-CHEMISTRY AND LIQUID REAGENT, Thrombosis and haemostasis, 1997, pp. 1230-1230
GLYCOPROTEIN IIB IIIA INHIBITORS CAN PREVENT HEPARIN MEDIATED PLATELET ACTIVATION IN HEPARIN-INDUCED THROMBOCYTOPENIA/
Authors: FAREED J YANG L BLAKEMORE C LEWIS BE JESKE W WALENGA JM HOPPENSTEADT D
Citation: J. Fareed et al., GLYCOPROTEIN IIB IIIA INHIBITORS CAN PREVENT HEPARIN MEDIATED PLATELET ACTIVATION IN HEPARIN-INDUCED THROMBOCYTOPENIA/, Thrombosis and haemostasis, 1997, pp. 1484-1484
AN ANTIPLATELET DRUG, TICLOPIDINE, INHIBITS HEPARIN-INDUCED THROMBOCYTOPENIA RESPONSES AS MEASURED BY PLATELET AGGREGOMETRY AND C-14 SEROTONIN RELEASE
Authors: ERO M JESKE W WALENGA JM YANG L LEWIS BE FAREED J PIFARRE R
Citation: M. Ero et al., AN ANTIPLATELET DRUG, TICLOPIDINE, INHIBITS HEPARIN-INDUCED THROMBOCYTOPENIA RESPONSES AS MEASURED BY PLATELET AGGREGOMETRY AND C-14 SEROTONIN RELEASE, Thrombosis and haemostasis, 1997, pp. 1827-1827
VALIDITY OF THE LABORATORY METHODS FOR THE DIAGNOSIS OF HIT - COMPARATIVE-STUDIES ON C-14 SEROTONIN RELEASE, ANTI-HEPARIN PLATELET FACTOR-4ANTIBODIES, PLATELET AGGREGOMETRY, LUMINESCENCE AGGREGOMETRY AND FLOWCYTOMETRIC METHODS
Authors: WALENGA JM JESKE W LEWIS BE FABBRINI N YANG L SZATKOWSKI E FASANELLA A HAAS S MESSMORE HL PIFARRE R
Citation: Jm. Walenga et al., VALIDITY OF THE LABORATORY METHODS FOR THE DIAGNOSIS OF HIT - COMPARATIVE-STUDIES ON C-14 SEROTONIN RELEASE, ANTI-HEPARIN PLATELET FACTOR-4ANTIBODIES, PLATELET AGGREGOMETRY, LUMINESCENCE AGGREGOMETRY AND FLOWCYTOMETRIC METHODS, Thrombosis and haemostasis, 1997, pp. 1840-1840
CLINICAL PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES ON ARGATROBAN TOOPTIMIZE THE ANTICOAGULANT DOSAGE IN INTERVENTIONAL CARDIOVASCULAR PROCEDURES
Authors: LEWIS BE IQBAL O HOPPENSTEADT D AHSAN A AHMAD S MESSMORE HL SCHWARZ RP WALENGA JM
Citation: Be. Lewis et al., CLINICAL PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES ON ARGATROBAN TOOPTIMIZE THE ANTICOAGULANT DOSAGE IN INTERVENTIONAL CARDIOVASCULAR PROCEDURES, Thrombosis and haemostasis, 1997, pp. 2010-2010
SUCCESSFUL USE OF ARGATROBAN IN CORONARY ANGIOPLASTY IN PATIENTS WITHHEPARIN-INDUCED THROMBOCYTOPENIA SYNDROME
Authors: LEWIS BE GRASSMAN E WRONA L RANGEL Y IQBAL O WALENGA JM FAREED J
Citation: Be. Lewis et al., SUCCESSFUL USE OF ARGATROBAN IN CORONARY ANGIOPLASTY IN PATIENTS WITHHEPARIN-INDUCED THROMBOCYTOPENIA SYNDROME, Thrombosis and haemostasis, 1997, pp. 2018-2018
MONITORING THE ANTICOAGULANT EFFECTS OF ARGATROBAN DURING CORONARY ANGIOPLASTY AND STENTING USING A POINT OF CARE DRY REAGENT TEST CARD SYSTEM AND ITS COMPARISON WITH ACT (HEMOTEC AND HEMOCHRON)
Authors: IQBAL O LEWIS BE RANGEL Y SCHWARZ R WALENGA JM
Citation: O. Iqbal et al., MONITORING THE ANTICOAGULANT EFFECTS OF ARGATROBAN DURING CORONARY ANGIOPLASTY AND STENTING USING A POINT OF CARE DRY REAGENT TEST CARD SYSTEM AND ITS COMPARISON WITH ACT (HEMOTEC AND HEMOCHRON), Thrombosis and haemostasis, 1997, pp. 2019-2019
PRE-EXISTENCE OF ANTI-PF4-HEPARIN ANTIBODIES IN PATIENTS NOT EXPOSED TO HEPARINS - RELEVANCE TO CLINICAL THROMBOCYTOPENIA
Authors: LEITZ H WALENGA JM FABBRINI N LEWIS BE FASANELLA A MESSMORE HL PIFARRE R
Citation: H. Leitz et al., PRE-EXISTENCE OF ANTI-PF4-HEPARIN ANTIBODIES IN PATIENTS NOT EXPOSED TO HEPARINS - RELEVANCE TO CLINICAL THROMBOCYTOPENIA, Thrombosis and haemostasis, 1997, pp. 2302-2302
FUNCTIONAL FACTOR-X LEVELS AS A MEANS TO ASSESS THE REVEL OF ORAL ANTICOAGULATION IN PATIENTS RECEIVING ANTITHROMBIN DRUGS
Authors: HOPPENSTEADT D LEWIS BE FABBRINI N LEITZ H FASANELLA A MESSMORE HL SCHWARZ R WALENGA JM
Citation: D. Hoppensteadt et al., FUNCTIONAL FACTOR-X LEVELS AS A MEANS TO ASSESS THE REVEL OF ORAL ANTICOAGULATION IN PATIENTS RECEIVING ANTITHROMBIN DRUGS, Thrombosis and haemostasis, 1997, pp. 2607-2607
PHARMACODYNAMICS OR THE ANTIPLATELET EFFECTS OF 2 GLYCOPROTEIN IIB IIIA TARGETING ANTIBODIES IN A PRIMATE MODEL/
Authors: FAREED J YANG L FU K HOPPENSTEADT D LEWIS BE BREDDIN HK
Citation: J. Fareed et al., PHARMACODYNAMICS OR THE ANTIPLATELET EFFECTS OF 2 GLYCOPROTEIN IIB IIIA TARGETING ANTIBODIES IN A PRIMATE MODEL/, Thrombosis and haemostasis, 1997, pp. 2713-2713
QUANTITATION OF TISSUE FACTOR AND TISSUE FACTOR PATHWAY INHIBITOR DURING PERCUTANEOUS TRANSROTATIONAL CORONARY ATHERECTOMY (PTRCA)
Authors: LABROO A RYAN P LEWIS BE JOHNSON S SCANLON P HOPPENSTEADT D WALENGA JM
Citation: A. Labroo et al., QUANTITATION OF TISSUE FACTOR AND TISSUE FACTOR PATHWAY INHIBITOR DURING PERCUTANEOUS TRANSROTATIONAL CORONARY ATHERECTOMY (PTRCA), Thrombosis and haemostasis, 1997, pp. 2935-2935
RESULTS OF PHASE-2 3 TRIAL OF ARGATROBAN ANTICOAGULATION DURING PTCA OF PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)/
Authors: LEWIS BE MATTHAI W GRASSMAN ED LEYA FS FAREED J WALENGA JM WRONA L RANGEL Y JOFFRION JL WHITLOW PL MCKEEVER LS
Citation: Be. Lewis et al., RESULTS OF PHASE-2 3 TRIAL OF ARGATROBAN ANTICOAGULATION DURING PTCA OF PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)/, Circulation, 96(8), 1997, pp. 1199-1199
Risultati: 1-25 | 26-50 | 51-58